Drug Evaluation Committee Issues and Causes of Health Communication between Patients/Citizens and Pharmaceutical Companies
June 2024
Communication regarding pharmaceutical information to patients and the public is becoming increasingly diverse. While various studies and initiatives have been conducted regarding the appropriate approach to health communication involving pharmaceutical companies, patient and public satisfaction still cannot be considered high.Consequently, we conducted a survey and root cause analysis focusing on three aspects of health communication between patients, citizens, and pharmaceutical companies—(1) information related to diseases and treatments, (2) information related to clinical trials, and (3) patient and citizen participation—to identify the causes of dissatisfaction among patients and citizens.
We hope that this report will contribute to the realization of better health communication between patients, citizens, and pharmaceutical companies in the future.
Japan Pharmaceutical Manufacturers Association, Drug Evaluation Committee,
Data Science Subcommittee, FY2023 Task Force 2-3